The treatment for hypercholesterolemia in children: Needs and worries;Il trattamento dell'ipercolesterolemia nei bambini: Necessità e preoccupazioni

Giornale Italiano di Cardiologia

Volumn 12, Issue 11, 2011, Pages 707-716

  Capuano, Vincenzo ^a,b   Rocco, Adriana ^c   Lamaida, Norman ^a,b   Capuano, Ernesto ^a,b  

^a Ospedale di Curteri   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c Pediatra   (Italy)

Author keywords

Hypercholesterolemia; Pediatric age; Statins

Indexed keywords

CHOLESTEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIET; DISEASE SEVERITY; FAMILIAL HYPERCHOLESTEROLEMIA; HOMOZYGOSITY; HUMAN; LIFESTYLE; LIVER TRANSPLANTATION; PHYSICAL ACTIVITY; PLASMAPHERESIS; POPULATION RESEARCH; REVIEW;

ADOLESCENT; CHILD; HUMANS; HYPERCHOLESTEROLEMIA;

EID: 82755192132     PISSN: 18276806     EISSN: None     Source Type: Journal    
DOI: 10.1714/966.10542     Document Type: Review

References (70)

1. Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated metaanalysis. Clin Ther 2009;31:236-44.
2. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 2008;178:576-84. (Pubitemid 351414005)
3. Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age. The Muscatine Study. Circulation 2001;104:2815-9. (Pubitemid 33126656)
4. Raitakari OT, Juonala M, Kahonen M, et al. Cardiovascular risk factors in childhood and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003;290:2277-83. (Pubitemid 37430560)
5. McGill HC Jr, McMahan CA, Zieske AW, Malcom GT, Tracy RE, Strong JP. Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile. Circulation 2001;103:1546-50. (Pubitemid 32226263)
6. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998;338:1650-6. (Pubitemid 28267909)
7. Stein EA. Statins and children: whom do we treat and when? Circulation 2007;116:594-5. (Pubitemid 47356344)
8. Pisciotta L, Priore Oliva C, Pes GM, et al. Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison. Atherosclerosis 2006;188:398-405. (Pubitemid 44301145)
9. Capuano V, Bambacaro A, D'Arminio T, Mazzotta G. White blood cell count is related to arterial pressure and cholesterolemia in normal children. Ital Heart J 2001;2:685-9. (Pubitemid 33040299)
10. Groner JA, Joshi M, Bauer JA. Pediatric precursors of adult cardiovascular disease: noninvasive assessment of early vascular changes in children and adolescents. Pediatrics 2006;118:1683-91. (Pubitemid 46393818)
11. Valenza M, Cattaneo E. Cholesterol dysfunction in neurodegenerative diseases: is Huntington's disease in the list? Prog Neurobiol 2006;80:165-76. (Pubitemid 44821504)
12. de Ferranti S, Ludwig DS. Storm over statins - the controversy surrounding pharmacologic treatment of children. N Engl J Med 2008;359:13:1309-13. Gli autori pubblicano delle interessanti riflessioni sul trattamento dei bambini con ipercolesterolemia, ammonendo a non trasferire i criteri terapeutici individuati per i piccoli pazienti con dislipidemia familiare ai bambini con soli fattori di rischio cardiovascolari.
13. Tamir I, Heiss G, Glueck CJ, Christensen B, Kwiterovich P, Rifkind BM. Lipid and lipoprotein distributions in white children ages 6-19 yr. The Lipid Research Clinics Program Prevalence Study. J Chronic Dis 1981;34:27-39. (Pubitemid 11203916)
14. Daniels SR, Greer FR; Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 2008;122:198-208. Gli autori definiscono i valori di riferimento per l'individuazione dei soggetti a rischio da trattare, delineano una strategia per il controllo su tutta la popolazione pediatrica, individuano un programma terapeutico attuabile.
15. Hickman TB, Briefel RR, Carroll MD, et al. Distributions and trends of serum lipid levels among United States children and adolescents ages 14-19 years: data from the Third National Health and Nutrition Examination Survey. Prev Med 1998;27:879-90. (Pubitemid 29010857)
16. Jolliffe CJ, Janssen I. Distribution of lipoproteins by age and gender in adolescents. Circulation 2006;114:1056-62. (Pubitemid 44358882)
17. Kavey RE, Allada V, Daniels SR, et al. Cardiovascular risk reduction in highrisk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006;114:2710-38. Importante documento dell'American Heart Association con chiare raccomandazioni per il trattamento dell'ipercolesterolemia in età pediatrica.
18. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003;111:1795-803. (Pubitemid 38057721)
19. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. New York, NY: McGraw-Hill, 2001:2863-913.
20. Cantafora A, Bertolini S, Calandra S. Familial hypercholesterolemia and mutations of the gene for low-density lipoproteins in Italy. Ann Ist Super Sanita 1999;35:177-84.
21. Maiorana A, Nobili V, Calandra S, et al. Preemptive liver transplantation in a child with familial hypercholesterolemia. Pediatr Transplant 2011;15:E25-E29.
22. Guardamagna O, Restagno G, Rolfo E, et al. The type of LDLR gene mutation predicts cardiovascular risk in children with familial hypercholesterolemia. J Pediatr 2009;155:199-204.e2.
23. Civeira F; International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004;173:55-68.
24. Wiegman A, Rodenburg J, de Jongh S, et al. Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children. Circulation 2003;107:1473-8. (Pubitemid 36378483)
25. Campagna F, Martino F, Bifolco M, et al. Detection of familial hypercholesterolemia in a cohort of children with hypercholesterolemia: results of a family and DNA-based screening. Atherosclerosis 2008;196:356-64.
26. DeMott K, Nherera L, Shaw EJ, et al. Clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners, 2008. http://www.nice.org.uk/CG71.
27. Wierzbicki AS, Humphries SE, Minhas R; Guideline Development Group. Familial hypercholesterolaemia: summary of NICE guidance. BMJ 2008;337:a1095. Pratico riassunto delle linee guida NICE sulla gestione dell'ipercolesterolemia familiare, con riferimento anche all'etàpediatrica.
28. Cefalù AB, Barbagallo CM, Sesti E, et al. Italian familial defective apolipoprotein B patients share a unique haplotype with other Caucasian patients. Clin Exp Med 2001;1:151-4. (Pubitemid 34143444)
29. Ouguerram K, Chetiveaux M, Zair Y, et al. Apolipoprotein B100 metabolism in autosomal- dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol 2004;24:1448-53. (Pubitemid 39050439)
30. Soutar AK, Naoumova RP. Autosomal recessive hypercholesterolemia. Semin Vasc Med 2004;4:241-8. (Pubitemid 40094488)
31. Berge KE. Sitosterolemia: a gateway to new knowledge about cholesterol metabolism. Ann Med 2003;35:502-11. (Pubitemid 37421561)
32. Wiesbauer F, Blassberger H, Azar D, et al. Familial-combined hyperlipidaemia in very young myocardial infarction survivors (&λε;40 years of age). Eur Heart J 2009;30:1073-9.
33. Shoulders CC, Jones EL, Naoumova RP. Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Hum Mol Genet 2004;13(Spec No 1):R149-R160. (Pubitemid 38443809)
34. Thompson GR. Primary hyperlipidaemia. Br Med Bull 1990;46:986-1004. (Pubitemid 20333680)
35. Emanuele E, Peros E, Minoretti P, et al. Apolipoprotein(a) size polymorphism is associated with coronary heart disease in polygenic hypercholesterolemia. Nutr Metab Cardiovasc Dis 2004;14:193-9. (Pubitemid 39462923)
36. Noto D, Cefalù AB, Barraco G, et al. Plasma non-cholesterol sterols: a useful diagnostic tool in pediatric hypercholesterolemia. Pediatr Res 2010;67:200-4.
37. American Academy of Pediatrics. National Cholesterol Education Program: report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992;89(3 Pt 2):525-84. Il primo importante documento approvato da una commissione di esperti sul problema dell'ipercolesterolemia nel bambino.
38. Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006;114:82-96. (Pubitemid 44305278)
39. Hayman LL, Meininger JC, Daniels SR, et al. Primary prevention of cardiovascular disease in nursing practice: focus on children and youth. A scientific statement from the American Heart Association Committee on Atherosclerosis, Hypertension, and Obesity in Youth of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council on Nutrition, Physical Activity, and Metabolism. Circulation 2007;116:344-57. (Pubitemid 47201829)
40. Robledo JA, Siccardi LJ, Cosio F, et al. Hypercholesterolemia reduction in children and adolescents after two years of intervention. Arch Argent Pediatr 2009;107:488-95.
41. Shamir R, Lerner A, Fisher EA. Hypercholesterolemia in children. Isr Med Assoc J 2000;2:767-71.
42. Centers for Disease Control and Prevention (CDC). Prevalence of abnormal lipid levels among youths - United States, 1999-2006. MMWR Morb Mortal Wkly Rep 2010;59:29-33.
43. The Writing Group for the DISC Collaborative Research Group. Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol. The Dietary Intervention Study in Children (DISC). JAMA 1995;273:1429-35.
44. Lifshitz F, Moses N. Growth failure: a complication of dietary treatment of hypercholesterolemia. Am J Dis Child 1989;143:537-42. (Pubitemid 19122528)
45. Koeijvoets KC, Rodenburg J, Hutten BA, Wiegman A, Kastelein JJ, Sijbrands EJ. Lowdensity lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial. Circulation 2005;112:3168-73. (Pubitemid 43113445)
46. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002;40:2117-21. (Pubitemid 36005896)
47. Kolansky DM, Cuchel M, Clark BJ, et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol 2008;102:1438-43.
48. Wierzbicki AS, Viljoen A. Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice. Drug Saf 2010;33:115-25.
49. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 2003;107:1562-6. (Pubitemid 36378499)
50. Jenkins DA, Wolever TM, Rao AV, et al. Effects on blood lipids of very high intakes of fiber in diets low in saturated fat and cholesterol. N Engl J Med 1993;329:21-6. (Pubitemid 23182874)
51. Dennison BA, Levine DM. Randomized, double-blind, placebo-controlled, two-period crossover clinical trial of psyllium fiber in children with hypercholesterolemia. J Pediatr 1993;123:24-9. (Pubitemid 23185193)
52. Martino F, Martino E, Morrone F, Carnevali E, Forcone R, Niglio T. Effect of dietary supplementation with glucomannan on plasma total cholesterol and low density lipoprotein cholesterol in hypercholesterolemic children. Nutr Metab Cardiovasc Dis 2005;15:174-80. (Pubitemid 40934161)
53. Deng R. Food and food supplements with hypocholesterolemic effects. Recent Pat Food Nutr Agric 2009;1:15-24.
54. Malinowski JM, Gehret MM. Phytosterols for dyslipidemia. Am J Health Syst Pharm 2010;67:1165-73.
55. Tammi A, Ronnemaa T, Gylling H, et al. Plant stanol ester margarine lowers serum total and low-density lipoprotein cholesterol concentrations of healthy children: the STRIP project. Special Turku Coronary Risk Factors Intervention Project. J Pediatr 2000;136:503-10. (Pubitemid 30469592)
56. Gheith O, Sheashaa H, Abdelsalam M, Shoeir Z, Sobh M. Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidemia: a preliminary report. Eur J Intern Med 2009;20:e57-e61.
57. Pignatelli P, Basili S. Nutraceuticals in the early infancy. Cardiovasc Ther 2010;28:236-45.
58. McCrindle BW, O'Neill MB, Cullen-Dean G, Helden E. Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial. J Pediatr 1997;130:266-73. (Pubitemid 27495163)
59. Colletti RB, Neufeld EJ, Roff NK, McAuliffe TL, Baker AL, Newburger JW. Niacin treatment in hypercholesterolemia in children. Pediatrics 1993;92:78-82.
60. Belay B, Belamarich PF, Tom-Revzon C. The use of statins in pediatrics: knowledge base, limitations and future directions. Pediatrics 2007;119:370-80. (Pubitemid 46397763)
61. Lambert M, Lupien PJ, Gagne C, et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics 1996;97:619-28. (Pubitemid 26138089)
62. de Jongh S, Ose L, Szamosi T, et al.; Simvastatin in Children Study Group. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-bind, placebo-controlled trial with simvastatin. Circulation 2002;106:2231-7. (Pubitemid 35222218)
63. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004;292:331-7. (Pubitemid 38944256)
64. Clauss SB, Holmes KW, Hopkins P, et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 2005;116:682-8. (Pubitemid 44336686)
65. Rodenburg J, Vissers MN, Wiegman A, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007;116:664-8. (Pubitemid 47356351)
66. van der Graaf A, Rodenburg J, Vissers MN, et al. Atherogenic lipoprotein particle size and concentrations and the effect of pravastatin in children with familial hypercholesterolemia. J Pediatr 2008;152:873-8.
67. Garcia-de-la-Puente S, Arredondo-Garcia JL, Gutierrez-Castrellon P, Bpjorquez-Ochoa A, Perez-Martinez MP. Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders. Pediatr Nephrol 2009;24:1205-10.
68. Avis HJ, Hutten BA, Gagne C, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 2010;55:1121-6.
69. Determinazione dell'Agenzia Italiana del Farmaco, 20 gennaio 2010. Gazzetta Ufficiale n. 22 del 28.01.10, pag. 74. Documento ufficiale del Ministero della Salute che introduce ed approva l'utilizzo delle statine nella popolazione pediatrica.
70. Clauss S, Wai KM, Kavey RE, Kuehl K. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr 2009;154:869-72.